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Abstract: Nerve growth factor (NGF) is a neurotrophic protein essential for the growth,
differentiation, and survival of sympathetic and sensory afferent neurons during development.
A substantial body of evidence, based on both animal and human studies, demonstrates that
NGF plays a pivotal role in modulation of nociception in adulthood. This has spurred
development of a variety of novel analgesics that target the NGF signaling pathway. Here,
we present a narrative review designed to summarize how NGF receptor activation and
downstream signaling alters nociception through direct sensitization of nociceptors at the site
of injury and changes in gene expression in the dorsal root ganglion that collectively increase
nociceptive signaling from the periphery to the central nervous system. This review illustrates
that NGF has a well-known and multifunctional role in nociceptive processing, although the
precise signaling pathways downstream of NGF receptor activation that mediate nociception
are complex and not completely understood. Additionally, much of the existing knowledge
derives from studies performed in animal models and may not accurately represent the human
condition. However, available data establish a role for NGF in the modulation of nociception
through effects on the release of inflammatory mediators, nociceptive ion channel/receptor
activity, nociceptive gene expression, and local neuronal sprouting. The role of NGF in
nociception and the generation and/or maintenance of chronic pain has led to it becoming
a novel and attractive target of pain therapeutics for the treatment of chronic pain conditions.
Keywords: nerve growth factor, nociception, sensitization, chronic pain
Introduction
Nerve growth factor (NGF) is a neurotrophic protein essential for the growth,
differentiation, and survival of sympathetic and sensory afferent neurons during
development.1 NGF contributes to neuronal phenotype by modulating axonal gui-
dance, gene transcription, neurotransmitter release, and synaptic plasticity.2–4 In
addition, NGF plays a pivotal role in the modulation of nociception in adulthood.5,6
This review highlights how NGF receptor activation and subsequent down-
stream signaling alter nociception. Specifically, we discuss how NGF can (i) in
a short time frame (typically within minutes) lead to direct sensitization of noci-
ceptors via actions at the site of injury, and (ii) in a longer time frame (several hours
to days) change gene expression and render nociceptors more responsive via actions
in the dorsal root ganglion (DRG). These actions contribute to anatomic remodeling
that results in a wider nociceptor input from injured tissue and increases the
nociceptive signaling from the periphery to the central nervous system (CNS),
providing a rationale for future study of novel analgesics that neutralize NGF or
antagonizes its receptors.
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Methods
This narrative review was intended to provide an overview
of the effects of NGF on nociceptive signaling. Due to the
broad scope of the review, and the substantial body of
published literature, a narrative approach was utilized.
The review was based on searches of PubMed and the
authors’ familiarity with the published literature. Search
terms included concepts related to NGF and pain or noci-
ception. Results included both animal and human studies.
Recent publications were prioritized, though older pivotal
studies were also included.
Results
Overview of NGF and Its Receptors
NGF (Figure 1) is a member of the neurotrophin family,
which in mammals also includes brain-derived neuro-
trophic factor (BDNF), neurotrophin-3, and neurotrophin-
4/5.7 NGF is initially translated as a precursor, proNGF,
which can be (i) cleaved intracellularly into mature β-NGF
by furin, (ii) cleaved extracellularly by plasmin or matrix
metalloproteinases, or (iii) remain intact and signal in its
proNGF precursor form.8–10 Inhibiting the processing of
proNGF abolishes regulated secretion of the resulting
mature NGF product.11
There are 2 receptors for NGF, p75 neurotrophin recep-
tor (p75NTR) and tropomyosin receptor kinase
A (TrkA).12 TrkA has a higher affinity for mature NGF
than for proNGF and activates neurotrophic signaling.9,13
P75NTR has a higher affinity for proNGF and can activate
both neurotrophic and apoptotic signaling, the later in the
presence of sortilin.8,14 There is an intricate functional
relationship between the 2 NGF receptors, and the signal-
ing outputs of NGF and proNGF (survival versus apopto-
sis) depend on the cellular context and the ratio of TrkA to
p75NTR.13
TrkA is expressed in nociceptive sensory neurons and
is thought to mediate most of the important effects of NGF
on the nociceptive system.6,23 In rats, about 40% of DRG
sensory neurons express TrkA, including peptidergic fibers
that innervate bone, skin, muscle, and viscera.6,23
Following the release of NGF, which frequently occurs at
sites of peripheral tissue injury, NGF can bind TrkA
receptors located at peripheral nociceptor terminals.
Upon binding of NGF to the extracellular region of
TrkA, the receptor dimerizes, autophosphorylates, and
initiates signaling events by docking and phosphorylating
downstream targets.24–26 The NGF-TrkA complex is
internalized into endosomes where it can be retrogradely
transported, recycled, or degraded.26 Immediate pro-
nociceptive effects resulting from NGF/TrkA signaling
(such as modulation of ion channel activity) occur in the
peripheral nociceptor terminal, while longer-term effects
(such as modification of gene expression) occur in the
soma following retrograde axonal transport of the NGF/
TrkA complex to the DRG.5,6 Three major signaling cas-
cades initiated by TrkA activation include the phospholi-
pase C-γ (PLCγ) pathway, the mitogen-activated protein
kinase (MAPK)/Erk pathway, and the phosphoinositide
3-kinase (PI3K) pathway.26
Figure 1 X-ray crystallographic structure of human NGF homodimer. NGF is
a homodimer consisting of 2 strands of 120 amino acids each, which non-
covalently dimerize to form a 26-kDa protein. Note the N-terminus of the mono-
mers is not apparent (unresolved). Copyright© 2006. Portland Press. Reproduced
with permission from Allen SJ, Dawbarn D. Clinical relevance of the neurotrophins
and their receptors. Clin Sci (Lond). 2006;110(2):175–191.7
Abbreviation: NGF, nerve growth factor.
Barker et al Dovepress
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Role of NGF on the Nociceptive System
During Development
A dominant effect of NGF during early development is its
role as a survival factor for neurons, including sympathetic
and sensory neurons.1,27 The density of the innervation of
the target tissue is controlled by a spatially and temporally
limited supply of NGF, and cells receiving insufficient
support during this critical period of time succumb to
cell death.28
NGF null mice have a severe loss of sympathetic and
sensory neurons, particularly in the population of pepti-
dergic small- and medium-diameter DRG neurons.30
Animals lacking TrkA receptors show a phenotype similar
to NGF null mice, underscoring the importance of NGF-
TrkA signaling for the development of the nociceptive
system.30,31
In humans, Hereditary Sensory and Autonomic
Neuropathy type V (HSAN V) is caused by mutations in
the NGF gene.32,33 The first mutation identified, a cytosine
to thymine point mutation at nucleotide 661, came from
analysis of a northern Swedish multi-generational
family.32,34 This particular NGF mutation results in
a substitution of tryptophan (W) for arginine (R) at
amino acid 221 in proNGF (R221W), which corresponds
to amino acid 100 in mature NGF (R100W).35 This muta-
tion causes a substantial loss of unmyelinated nerve fibers
and a moderate loss of thinly myelinated fibers.32 Patients
with this mutation present with impaired ability to sense
deep pain (pain originating in the bones or joints) and
temperature (thresholds for heat and cold sensing are
increased), but most other neurological functions, includ-
ing sweating, appear normal.32 This mutation does not
affect NGF binding to TrkA but does reduce PLC signal-
ing downstream of TrkA.35 This NGF mutation also inhi-
bits processing of proNGF to mature NGF, which may
lower systemic NGF levels, and abolishes NGF binding
to p75NTR.34,35 Other mutations can alter the spectrum of
HSAN V presentation. For example, a cytosine to adeno-
sine mutation at nucleotide 680 (C680A) causes complete
insensitivity to pain accompanied by anhidrosis, mild men-
tal retardation, and immune deficiency.33 Thus, different
HSAN V NGF gene mutations may have a variety of
effects on NGF-sensitive tissues.
Mutations in the TrkA gene cause a related disorder,
HSAN IV, which produces a phenotype similar to HSAN
V.36 These TrkA gene mutations result in defective binding
of NGF to TrkA and, as a result, the inhibition of NGF-
induced TrkA phosphorylation and downstream signaling
cascades.37
As development proceeds, the role of NGF in neuronal
growth/survival during development diminishes and its role
in modulating nociception becomes more relevant.6 It is
likely that the developmental role of NGF and the nocicep-
tive role of NGF overlap temporally. The ability of NGF to
modulate nociceptive signaling has been observed during
early perinatal stages, with repeated postnatal (P0-14) expo-
sure to exogenous NGF in rodents producing mechanical
hyperalgesia that persists into adulthood.38 Further, the abil-
ity of NGF to sensitize sensory neurons to capsaicin or heat
stimuli begins between postnatal days 4 to 10.39
Evidence for a Role of NGF Signaling in
Nociception in Adulthood
NGF Levels are Increased During Pain Conditions
Though adult sensory and sympathetic neurons can sur-
vive in the absence of NGF, NGF remains capable of
promoting neuronal growth and sprouting in
adulthood.40–43 Basal NGF levels are lower in the adult
than in development.42,44 In humans, serum NGF levels
start to decrease at approximately 8 years of age, presum-
ably reflecting increasing maturity of the nervous
system.45 Levels of NGF increase in adult rodents in
several inflammatory conditions and in several models of
pain.46–49 Further, blockage of NGF signaling can attenu-
ate pain-related behavior in a variety of animal models
including immune arthritis, fracture, bone cancer pain,
osteoarthritis, and neuropathic pain.50–60 Increased levels
of NGF are also found in chronic pain conditions in
humans, such as osteoarthritis, low back pain, and inter-
stitial cystitis (Table 1).61–77 However, an elevated level of
NGF is not a hallmark of all chronic pain conditions and
low levels of NGF have been found in the plasma of
patients with fibromyalgia.78 Thus, care should be taken
when generalizing findings from one condition to another.
It should also be noted that the physiologically relevant
level of NGF required for neuronal sensitization at local
sites of peripheral tissue injury is not known. It is also
unclear how NGF levels at local sites of peripheral injury
are correlated to overall levels measured in serum or other
fluids.
NGF Administration Induces Hyperalgesia
In addition to the observation of increased NGF levels in
chronic pain conditions and animal models of pain/inflam-
mation, it has been demonstrated that exogenous
Dovepress Barker et al
Journal of Pain Research 2020:13 submit your manuscript | www.dovepress.com
DovePress
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Table 1 Summary of Disease States or Conditions in Humans in Which Increased Levels of NGF Were Detected Compared with
Controls
Study Disease/Condition Sample Size Sample Matrix NGF
Form
Aloe et al61 Rheumatoid arthritis,
osteoarthritis, or other
chronic arthritis
n = 6 osteoarthritis patients; n = 8 rheumatoid arthritis patients;
n = 8 patients with other chronic arthritis; n = 2 control
patients who did not have rheumatic disease
Synovial fluid Protein
Halliday et al62 Rheumatoid arthritis or
other inflammatory
arthropathy
n = 13 rheumatoid arthritis patients; n = 10 other inflammatory
arthropathies; n = 3 normal volunteers
Synovial fluid Protein
Walsh et al63 Rheumatoid arthritis or
osteoarthritis
n = 10 rheumatoid arthritis patients; n= 11 osteoarthritis
patients; n = 11 non-arthritic post-mortem controls
Vascular channels
of osteochondral
junction
Protein
Iannone et al13 Osteoarthritis n = 12 osteoarthritis patients; n = 3 healthy controls Knee
chondrocytes
Protein
Jiang et al65 Interstitial cystitis/bladder
pain syndrome
n = 30 interstitial cystitis/bladder pain syndrome patients; n = 26
controls
Blood serum Protein
Okragly et al66 Interstitial cystitis or
bladder cancer
n = 4 interstitial cystitis patients; n = 6 bladder transition cell
cancer-carcinoma patients;
n = 7 urinary tract infection patients; n = 7 healthy volunteers
Urine Protein
Liu et al67 Interstitial cystitis/bladder
pain syndrome
n = 58 interstitial cystitis/bladder pain syndrome patients; n = 28
healthy controls
Urine Protein
Lowe et al68 Idiopathic sensory urgency,
chronic cystitis, or
interstitial cystitis
n = 4 patients with idiopathic sensory urgency; n = 4 chronic
cystitis patients; n = 4 interstitial cystitis patients; n = 4 controls
(genuine stress incontinence on cystometry but with no
irritative symptoms)
Urothelium Protein
Watanabe et al69 Chronic prostatitis (CP) or
chronic pelvic pain
syndrome (CPPS)
n = 20 CP or CPPS patients; n = 4 healthy male controls with no
history of genitourinary symptoms, instrumentation, or surgery
Expressed
prostatic
secretions
Protein
Giovenga et al70 Primary fibromyalgia
syndrome
n = 34 fibromyalgia syndrome patients; n = 15 patients
diagnosed with fibromyalgia in addition to another painful or
inflammatory condition; n = 10 other (patients diagnosed with
another painful or inflammatory condition, but not
fibromyalgia); n = 35 healthy controls
Cerebrospinal
fluid
Protein
Sarchielli et al71 Chronic daily headache n = 20 chronic daily headache patients; n = 20 age-matched
controls who underwent lumbar puncture for diagnostic
purposes
Cerebrospinal
fluid
Protein
Sobue et al72 Various neuropathiesa n = 54 neuropathy; n = 4 specimens with normal appearance of
morphology and normal nerve conduction
Sural nerve
segments
mRNA
Freemont et al73 Low back pain n = 21 “pain level” (discography at these levels reproduced the
patients’ symptoms of low back pain and/or sciatica)
intervertebral disc (IVD) specimens; n = 20 “non-pain level”
(discography was either painless or induced sensations that
were not described by the patient as mimicking their symptoms)
IVD specimens. A total of 41 specimens were taken from 36
patients
Intervertebral
disc
mRNA
(Continued)
Barker et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Journal of Pain Research 2020:131226
 
Jo
ur
na
l o
f P
ai
n 
R
es
ea
rc
h 
do
w
nl
oa
de
d 
fr
om
 h
ttp
s:
//w
w
w
.d
ov
ep
re
ss
.c
om
/ b
y 
62
.1
07
.3
2.
10
1 
on
 1
8-
Ju
n-
20
20
F
or
 p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
administration or overexpression of NGF results in hyper-
algesia and/or allodynia.38,79-81
Interestingly, striking hyperalgesic effects of NGF
administration have also been observed in humans. In
healthy adults, for example, a single subcutaneous injec-
tion of recombinant NGF has been shown to elicit local
injection-site hyperalgesia that persists for up to 7 weeks,
depending on the dosage.82 Likewise, intradermal injec-
tion of NGF produces long-lasting local thermal (early
onset) and mechanical (delayed) hyperalgesia.83–87
Localized priming of nociceptors following intradermal
injection of NGF has also been demonstrated through an
enhancement of hyperalgesia in response to irradiation
with ultraviolet-B.88,89
Intramuscular injection of NGF has been shown to
cause lasting mechanical hyperalgesia in a variety of
muscles.90–101 Notably, injection of NGF into the tibialis
anterior muscle induces local mechanical hyperalgesia
within 3 hours of injection that spreads to distant areas
on days 1 to 4, suggesting involvement of central pain
mechanisms.93 Repeated injections result in both temporal
summation and spreading of mechanical pain, again impli-
cating both peripheral and central mechanisms.102
Spreading of NGF-induced hyperalgesia has also been
observed following injection into the supraspinatus
muscles.94 A single injection of NGF into the facia of
the musculus erector spinae muscle produces both
mechanical and chemical (proton) hyperalgesia.103
Chemical hyperalgesia has also been demonstrated follow-
ing the injection of NGF into the tibialis anterior.101
NGF Treatment Lowers Nociceptor Activation
Threshold
Intradermal injection of NGF increases the conduction velo-
city and decreases activity-dependent slowing of conduction
velocity in unmyelinated porcine (pig) mechano-insensitive
nociceptors.104–106 The activation threshold of mechano-
sensitive nociceptors at the injection site decreases following
NGF treatment and the proportion of mechano-sensitive
nociceptors increases.104 While the receptive field of these
nociceptors increased, there was no increase in intraepider-
mal nerve fiber density, suggesting that previously silent
nociceptors may be recruited in this circumstance.104 These
changes were measured 3 weeks after NGF administration
and, therefore, likely represent long-term effects of NGF
signaling. Sensitization of skin nociceptors has been con-
firmed in humans using microneurography techniques
which demonstrate that axonal branches exhibit reduced
activation thresholds within the NGF injection zone but not
outside of the injection zone.107
Nociceptive Actions of NGF Signaling
Effects of NGF on Inflammatory Cells and Mediators
There is evidence that NGF modulates nociception, in part,
by influencing the actions of inflammatory cells and media-
tors. It has been shown that rodent mast cells produce and
store NGF in granules until degranulation and NGF mRNA
has been detected in a human mast cell line.108,109 Moreover,
cultured media from this mast cell line is able to induce
neurite outgrowth in cultured chick embryonic sensory neu-
rons, suggesting that NGF is secreted from these cells.109
Table 1 (Continued).
Study Disease/Condition Sample Size Sample Matrix NGF
Form
Richardson
et al74
Low back pain n = 5 samples from 4 non-degenerate post-mortem nucleus
pulposus (NP) patients; n = 9 post-mortem degenerate NP
samples from 4 patients; n = 13 surgical degenerate NP samples
from 11 patients
Nucleus pulposus mRNA
Aoki et al75 Lumbar degenerative disc
disease
n = 29 patients with herniated discs; n = 26 patients with other
degenerated disc diseasesb
Nucleus pulposus Protein
Zhu et al76 Pancreatic cancer n = 37 pancreatic cancer patients; n = 27 pancreatic samples
from humans free of pancreatic disease through an organ donor
program in which there were no candidates for transplantation
Pancreatic cancer
tissuec
mRNA
Notes: aPatients included had vasculitic and ischemic neuropathy; inflammatory demyelinating neuropathy with Guillain–Barre syndrome or chronic inflammatory
demyelinating neuropathy; alcoholic neuropathy; familial amyloid polyneuropathy type 1; toxic neuropathy with cisplatin; Charcot–-Marie–Tooth disease type 1; X-linked
recessive bulbospinal neuronopathy; diabetes mellitus; hypothyroidism; or neuropathy with unknown origin. bOther degenerated disc diseases were spondylolisthesis, spinal
canal stenosis, and lumbar degenerative scoliosis. cTaken from patients undergoing a partial duodenopancreatectomy for pancreatic cancer.
Dovepress Barker et al
Journal of Pain Research 2020:13 submit your manuscript | www.dovepress.com
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NGF has also been found to be present in, and released from,
human CD14+ T cell clones and human monocytes.110,111
NGF has been shown to increase the release of mediators
from inflammatory cells (Figure 2). These mediators, such as
bradykinin, histamine, ATP, serotonin, and protons, are
released during inflammation or injury from ruptured cells or
from infiltrating inflammatory cells and are capable of activat-
ing receptors and ion channels found on the peripheral noci-
ceptor terminal, leading to neuronal depolarization and
sensitization that manifests as pain hypersensitivity.112 For
example, exogenous IL-1β causes mechanical and thermal
hyperalgesia (measured as an increased nociceptive reflex) in
rodents, and histamine has been shown to mediate pain-related
behaviors in a rodent model of interstitial cystitis.113,114
Further, serotonin administered to healthy human volunteers
causes mechanical hyperalgesia and stimulates calcium influx
into cultured rat sensory neurons, an indication of cell
excitability.115,116 Finally, bradykinin treatment causes
mechanical hyperalgesia in rats and Protein Kinase C (PKC)
signaling-dependent sensitization of the transient receptor
potential cation channel subfamily V member 1 (TRPV1),
when isolated via patch-clamp, which has a known role in
nociception and noxious heat sensation.117,118
NGF can trigger the release of histamine and leukotriene
from human basophils, serotonin and histamine from rodent
mast cells, and histamine and tryptase from a human mast cell
line.119–123However,NGFadministration did not activatemast
cells in a separate rodent study, and there is some evidence that
rodent mast cells do not express NGF receptors.109,124 Though
the contribution of mast cells to NGF signaling in humans is
not clear, human mast cells express TrkA receptors and, thus,
species differences must be considered when discussing the
influence of NGF on inflammatory cells.109 Similar to effects
seen in mast cells, isolated murine peritoneal macrophages
exposed to NGF increase the production of interleukin 1β
(IL-1β).125 This may occur through TrkA activation as TrkA
expression, but not p75NTR expression, was observed in these
cells.125 The effects that NGF-mediated release of inflamma-
tory mediators have will depend on the tissue. For example,
histamine evokes the sensation of itch when released in isola-
tion in superficial skin and mucous membranes, but causes
burning pain when applied to deep somatic tissues.126,127
In addition to affecting cytokine release, NGF can also
affect the actions of inflammatory mediators. For example,
NGF can potentiate the sensitivity of rat DRG neurons to
bradykinin.128 On the other hand, inflammatory mediators
can influence the levels and effects of NGF. Evidence suggests
that IL-1β contributes to increased NGF levels in cultured
sciatic nerve explants, and inhibiting bradykinin-1 receptor
activity blocks NGF-induced thermal hyperalgesia in
rodents.114,129,130 Thus, there may be instances of positive
feedback loops in vivo in which NGF stimulates the release
and actions of inflammatory mediators that in turn stimulate
increased synthesis and/or release of NGF. However, the role,
if any, such a feedback loop plays in the generation or main-
tenance of chronic pain is not known.
NGF Effects on Nociceptive Ion Channels,
Receptors, and Peptides
In addition to enhancing the release of inflammatory med-
iators that alter sensory neuron excitability, NGF signaling
itself also has effects on the activity of nociceptive ion
Figure 2 Nociceptive effects of NGF on inflammatory cells. NGF binds TrkA receptors on inflammatory cells. The resulting NGF/TrkA signaling increases the release of
a variety of inflammatory mediators such as serotonin, histamine, and NGF itself, which are known to cause sensitization of nociceptors via modulation of receptor or ion
channel activity at the peripheral terminal.
Abbreviations: 5-HT, 5-hydroxytryptamine (serotonin); NGF, nerve growth factor; TrkA, tropomyosin receptor kinase A.
Barker et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
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channels and receptors that contribute to nociceptor sensi-
tization (Table 2). The changes may be due either to direct,
immediate effects on ion channel/receptor activity at the
cell membrane and/or through longer-term effects such as
enhanced gene transcription that leads to increased num-
bers of ion channels/receptors at the cell surface
(Figure 3).
NGF Effects in Ion Channel Activity
The cation channel TRPV1, known to play a key role
in nociception, is modulated by NGF activity. Cell
culture studies have implicated each of the major sig-
naling pathways downstream of TrkA activation in
NGF-induced sensitization of TRPV1, though data par-
ticularly support a role for PI3K as a mediator of
TRPV1 sensitization.131–135 Another non-selective
cation channel predominantly expressed in sensory
neurons, the ATP-gated P2X3 receptor, is also modu-
lated by NGF.136–138 Cultured rodent trigeminal sen-
sory neurons exposed to NGF exhibit potentiated P2X3
currents, while blocking NGF activity reduces such
currents.137,138 NGF-induced enhancement of P2X3
activity may occur downstream of TrkA activation, as
PKC-mediated phosphorylation of P2X3 threonine sub-
units has been shown to increase P2X3 currents in
these cultured neurons.137,139
In isolated rat primary DRG sensory neurons, NGF
enhances tetrodotoxin-resistant sodium currents and sup-
presses delayed rectifier potassium currents, which together
lead to increased cell excitability.140 Signaling molecules
downstream of TrkA activation have been shown to potenti-
ate sodium channel activation. In cultured rodent DRG neu-
rons, for example, Nav1.7 activation is increased via Erk1/2
signaling, and activation of p38 MAPK can directly phos-
phorylate Nav1.8 leading to an increase in Nav1.8 current
density in DRG neurons.141,142 However, whether these
changes to sodium channel activation properties occur down-
stream of NGF-TrkA signaling, or as part of other signaling
pathways, was not explored in these studies.
While numerous studies have demonstrated a role for
NGF-TrkA signaling in the modulation of nociceptive ion
channel activity, there is also evidence that NGF-p75NTR
Table 2 Summary of Short- and Intermediate/Long-Term Effects of NGF Signaling on Ion Channels, Receptors, and Peptides
Term Effect Downstream Signaling Pathways Possibly Involved
Short-term (typically within
a few minutes)
● Increased TRPV1 channel activity.131,134 ● PLC/PKC, MAPK/ErK, Likely PI3K.131–134
● Increased P2X3 channel activity.137 ● PLC/PKC.137
● Increased tetrodotoxin-resistant sodium channel
activity.140
● Not identified
● Decreased delayed rectifier potassium channel
activity.140
● Not identified
● Increased calcium channel activity.202 ● Not identified
● Increased NMDA receptor activity.203 ● Possible direct interaction.203
Longer-term (typically
several hours to days)
● Increased NaV1.8 synthesis.204 ● Not identified
● Increased NMDA receptor subtype 2B synthesis.148 ● Not identified
● Increased synthesis of TRPV1.149 ● Not identified
● Increased synthesis of voltage-gated calcium
channels.205
● Not identified
● Increased synthesis of P2X3.153 ● Not identified
● Increased BK2R synthesis.128,154 ● Not identified
● Increased activity of ASIC channels.156 ● Not identified
● Increased ASIC1a synthesis.158 ● Not identified
● Increased ASIC3 synthesis.157 ● NGF/TrkA and downstream PLC/PKC. NGF/p75NTR and
downstream JNK/p38 MAPK.157
● Increased substance P synthesis.159,160,174 ● Not identified
● Increased CGRP synthesis.47,159,174 ● Not identified
● Increased BDNF synthesis.179,206 ● Not identified
Abbreviations: ASIC, acid-sensing ion channel; BDNF, brain-derived growth factor; BK2R, bradykinin receptor 2; CGRP, calcitonin gene-related peptide; ERK,
extracellular signal-regulated kinase; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; NGF, nerve growth factor; NMDA, N-methyl-D-aspartate;
P2X3, P2X purinoceptor 3; PI3K, phosphoinositide 3-kinase; PKC, protein kinase C; PLC, phospholipase C; TrkA, tropomyosin receptor kinase A; TRPV1, transient
receptor potential cation channel subfamily V member 1.
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Figure 3 Effects of NGF on nociceptive ion channels, receptors, and peptides. (A) NGF signaling increases the activity of a variety of ion channels and receptors at the
nociceptor peripheral terminal, which promotes depolarization and sensitization in a relatively short time frame. In a longer time frame, the NGF/TrkA complex is
retrograde transported to the soma where NGF/TrkA signaling within the DRG promotes gene expression and leads to an upregulation of nociceptive ion channels,
receptors, and peptides in the peripheral and central terminals. (B) NGF is released from a variety of cells following inflammatory injury. Reproduced with permission from
Mantyh PW, Koltzenburg M, Mendell LM, Tive L, Shelton DL. Antagonism of nerve growth factor-TrkA signaling and the relief of pain. Anesthesiology (Official Journal of the
American Society of Anesthesiologists). 2011;115(1):189–206; https://anesthesiology.pubs.asahq.org/article.aspx?articleid=1933906.
Abbreviations: ASIC3, acid-sensing ion channel 3; BDNF, brain-derived neurotrophic factor; BR, bradykinin receptor; Ca, calcium; CGRP, calcitonin gene-related peptide;
DRG, dorsal root ganglion; K, potassium; Na, sodium; NGF, nerve growth factor; SP, substance P; TrkA, tropomyosin receptor kinase A; TRPV1, transient receptor potential
cation channel subfamily V member 1.
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signaling can contribute to sensory neuron
excitability.6,143-145 For example, NGF-mediated activa-
tion of p75NTR has been shown to increase ceramide
levels in a TrkA-independent manner in cell culture, and
studies in rodents have shown that ceramide likely med-
iates NGF-induced sensitization of isolated sensory neu-
rons in vitro and possibly NGF-induced pain-related
behaviors in vivo.140,146,147
NGF Effects on Gene Expression
In addition to enhancing the activity of nociceptive ion
channels to promote depolarization and sensitization in
a short time frame, NGF also mediates longer-term
changes in gene expression and/or membrane localiza-
tion, both of which contribute to increased sensory neuron
excitability. For example, intramuscular injection of NGF
into the masseter of rats causes an increase in the number
of trigeminal ganglion neurons expressing the N-methyl-
D-aspartate (NMDA) receptor subtype 2B, an increase
that peaks after 3 days and is associated with mechanical
sensitization.148 NGF has also been shown to promote
TRPV1 transcription in PC12 cells and increase translo-
cation of TRPV1 protein to the cell surface of cultured
rodent DRG neurons, the latter possibly mediated through
PI3K and/or PKC signaling events downstream of
TrkA.134,149–151 Increased expression of sodium channels
is evident in DRG neurons, accompanied by behaviors
associated with thermal and mechanical allodynia, after
subcutaneous administration of NGF in rats.152
Intrathecal administration of NGF in rats causes novel
P2X3 expression in axons projecting to lamina I and
outer lamina II of the spinal cord.153 In freshly isolated
mouse DRG, NGF exposure increases bradykinin B2
receptor mRNA and membrane expression.154 Likewise,
a separate study found that NGF treatment increases the
number of bradykinin binding sites in these cells, which is
dependent on the presence of p75NTR.155
Proton-gated acid-sensing ion channels (ASIC) levels
may also be modulated by NGF. In cultured rodent DRG
neurons, a mixture of inflammatory mediators including
NGF, serotonin, interleukin-1, and bradykinin signifi-
cantly increase ASIC3 currents, and NGF is known to
increase ASIC3 expression.156,157 In humans, local NGF-
induced hyperalgesia in the tibialis anterior muscle is
enhanced by subsequent treatment with acid, an activator
of ASIC channels.101 In this study, however, acute acid-
induced pain was not enhanced by previous intramuscular
injection of NGF.101 This contrasts with a separate human
study in which injection of NGF into the fascia of the
Musculus erector spinae muscle enhanced painful
responses to acidic saline treatment compared with con-
trol saline.103 This difference may be due to the time
required for retrograde transport of the NGF signaling
complex to the DRG, since acid treatment occurred 7
and 14 days after NGF administration in the former
study (enhanced acid response) and only 1 day after
NGF administration in the latter study (no enhancement
of acid response).101,103 NGF signaling increases ASIC3
expression through a p75NTR-dependent transcriptional
switch in primary cultured rat DRG neurons.157 NGF
controls a basal-level of ASIC3 transcription through
constitutive activation of TrkA/PLC/PKC signaling,
while increased levels of NGF promote ASIC overexpres-
sion via combined PLC/PKC and JNK/p38 MAPK sig-
naling that depends on the presence of p75NTR.157
ASIC1a protein expression has also been shown to
increase following NGF treatment of cultured rat
DRGs.158
Overall, the cellular processes mediating NGF-induced
upregulation of ion channel membrane expression are not
completely delineated and may involve a combination of
effects on transcription, translation, and exocytosis.
NGF Effects on Peptides
NGF has also been shown to increase levels of peptides
expressed by nociceptors including substance P and calci-
tonin gene-related peptide (CGRP), both of which are
increased during inflammation.47,159,160 NGF-mediated
increases in substance P protein levels occur downstream
of both TrkA and p75NTR activation in cultured rat sen-
sory neurons.160 While NGF’s effects on nociceptive ion
channels and cell surface receptors sensitize the nociceptor
(more action potentials over time), NGF’s ability to
enhance neurotransmitter release (substance P and
CGRP) potentially increases neurotransmission indepen-
dent of increases in the number of action potentials. This
synergistic effect makes NGF a novel therapeutic target
relative to other known neuronal mediators such as brady-
kinin and serotonin.
NGF Effects on Nerve Sprouting
First-in-human studies using recombinant human NGF
were designed to prevent or reverse peripheral
neuropathy.161 Phase 3 clinical trials not only failed to
demonstrate a significant beneficial effect, but it was also
observed that NGF injection produced generalized
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myalgia and localized hyperalgesia at the injection
site.161 This observation revealed that intradermal NGF
injections could be used as an experimental model for
hyperalgesia and opened the door into research on how
NGF modulates pain signaling. One thought was that
local peripheral neuronal sprouting of sensory nerves
can increase nerve terminal density in peripheral tissues.
Such anatomical remodeling at sites of injury or inflam-
mation could, potentially, contribute to increased nocicep-
tive input and increased pain perception. For example,
pathological sensory and/or sympathetic nerve sprouting,
sometimes resulting in the formation of painful neuroma-
like structures, has been observed in disease models of
bone cancer pain and arthritis pain.49,53,54,162 Evidence
suggests that NGF can drive neuronal sprouting
(Figure 4). For example, administration of NGF antibody
inhibits sprouting and neuroma formation in the afore-
mentioned models of bone and arthritis pain.53–55,163
In addition to its effect at peripheral sites, NGF may
also play a role in neuronal sprouting at sites such as the
DRG and dorsal horn of the spinal cord.164–166 For exam-
ple, axonal sprouting of peptidergic nociceptive neurons in
the dorsal horn and into the ventral horn of the spinal cord
can be induced by adenovirus-driven overexpression of
NGF in rats.165,166 Such sprouting leads to chronic pain,
characterized by thermal-mechanical and hyperalgesia, in
these animals.165,166
Although aberrant nerve sprouting has been seen in
animal models of pain and evidence suggests this is NGF-
dependent, the exact signaling pathways downstream of
NGF receptor activation are unknown. Under in vitro
experimental conditions, chick DRG axonal sprouting
towards NGF-coated beads is blocked both by treatment
with a pan-Trk inhibitor and with PI3K inhibition, consis-
tent with the hypothesis that pathological sprouting may be
mediated by NGF-TrkA signaling pathways.167
Figure 4 Preventative administration of anti-NGF antibody reduces metastatic prostate cancer-induced CGRP+ and NF200+ sensory nerve sprouting. (A andD) CGRP+ and NF200
+ innervation of the bone marrow in sham-operated mice (yellow). (B and E) 26 days post-injection. Proliferation of prostate cancer cells (transfected with green fluorescent protein;
green) and increased sprouting of CGRP+ and NF200+ fibers (yellow). (C and F) Effects of anti-NGF antibody (mAb911) administered at 10, 15, 20, and 25 days after cell injection.
CGRP+ and NF200+ nerve sprouting has significantly reduced. Republished with permission from Pathological Sprouting of Adult Nociceptors in Chronic Prostate Cancer-Induced
Bone Pain. Juan M. Jimenez-Andrade, Aaron P. Bloom, James I. Stake, William G. Mantyh, Reid N. Taylor, Katie T. Freeman, Joseph R. Ghilardi, Michael A. Kuskowski and Patrick W.
Mantyh. J Neurosci. 2010;30 (44) :14649-14656.163 https://doi.org/10.1523/JNEUROSCI.3300-10.2010.
Abbreviations: CGRP, calcitonin gene-related peptide; GFP, green fluorescent protein; NF200, 200-kDa neurofilament; NGF, nerve growth factor.
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NGF also mediates sprouting of TrkA+ sympathetic
nerve fibers.168–171 Exogenous administration of NGF in
adult mice, for example, leads to increased adrenergic
nerve sprouting in several peripheral organs and in the
brain.168 An increase in sympathetic drive may represent
another mechanism through which NGF contributes to
pain. For example, increased sympathetic signaling plays
a role in the maintenance of pain associated with complex
regional pain syndrome (CPRS) and elevated sympathetic
activity increases the spatial distribution of hyperalgesia in
these patients.172,173
NGF Effects Within the CNS
As discussed above, NGF signaling contributes to acute
and long-term nociceptive hypersensitivity by increasing
the activity and/or expression of nociceptive ion channels,
receptors, and peptides in the periphery. However, NGF
may also have sensitizing effects within the CNS.
NGF has been shown to affect levels of nociceptive
peptides within the CNS. Repeated subcutaneous admin-
istration of NGF increases CGRP and substance P release
at central afferent terminals of sensory neurons in
rodents.174 CGRP increases neuronal excitability of spinal
neurons and substance P has been shown to increase dorsal
horn neuron excitability by potentiating NMDA activity in
these animals.175–177 NGF also affects BDNF levels,
a neurotrophin that is expressed by some TrkA+ sensory
neurons, and BDNF release in the spinal cord is thought to
contribute to the central sensitization thought to underlie
many chronic pain conditions.178 In adult rats, BDNF
mRNA levels are selectively increased in TrkA-
expressing DRG cells in response to intrathecal adminis-
tration of NGF.179 Following NGF treatment, BDNF is
retrogradely and anterogradely transported from the DRG
to the peripheral and central sensory nerve terminals.179,180
BDNF is also released directly in the dorsal horn follow-
ing electrical stimulation of dorsal roots in isolated rat
dorsal horns, and this release is enhanced by systemic or
intrathecal NGF administration.181 BDNF increases sen-
sory neuron excitability via binding to p75NTR and sub-
sequent downstream sphingosine kinase signaling.182
BDNF can also sensitize rodent spinal lamina II neurons
via NMDA receptor activation and PLC/PKC signaling,
though it is not known whether the PLC/PKC signaling
pathway is initiated downstream of TrkA activation in this
case.183
NGF may also play a role in wind-up, the process by
which central neuron excitability is increased following
repeated low-frequency stimulation.184 Isolated rat spinal
cords treated with NGF exhibit a novel wind-up response
with low-frequency stimulation of group I/II Aβ fibers that
were found to be mediated through enhanced neurokinin-1
receptor activation.185
Overall, NGF signaling initiated at distal peripheral
locations can have long-lasting effects within the CNS
that may contribute to chronic pain (Figure 5). A single
subcutaneous administration of NGF in the rat, for exam-
ple, causes transient thermal and mechanical allodynia (up
to 24 hours), but persistent (up to 3 months) increases in
sodium channel levels within neurons of the DRG.152
Future Perspectives
Given the role of NGF in the modulation of nociception,
the analgesic benefits of drugs targeting the NGF pathway
have been explored in pre-clinical pain models and in
human studies. Monoclonal antibodies against NGF (eg,
tanezumab and fasinumab) that bind and neutralize NGF
activity are in late stages of clinical development, having
demonstrated significant analgesic effects over placebo in
Phase 2 or Phase 3 trials of osteoarthritis.186–196 Small
molecule TrkA inhibitors (ASP7962 and GZ389988A)
have advanced to Phase 2 clinical testing with mixed
results. A single intra-articular injection of the TrkA inhi-
bitor GZ389988A has been shown to modestly improve
osteoarthritis knee pain at 8 weeks.197 In contrast, treat-
ment with the oral TrkA inhibitor ASP7962 at a dose of
100 mg BID failed to improve pain and function in
patients with knee osteoarthritis after 4 weeks of
treatment.198 Finally, a Phase 1 trial of LEVI-04, an inject-
able p75NTR fusion protein designed to bind excess NGF,
is currently recruiting healthy volunteers and patients with
knee OA (NCT03227796).
Other novel pain therapeutics targeting the NGF path-
way are in the early stages of discovery or pre-clinical
development. These include monoclonal antibodies that
bind and neutralize TrkA and small molecule NGF/pro-
NGF inhibitors that disrupt NGF/proNGF binding to TrkA
and p75NTR.199–201 While still in early developmental
stages, these small molecule-based inhibitors may be of
therapeutic interest in attenuating NGF-induced sensitiza-
tion of nociceptive signaling pathways.
The nociceptive signaling pathways mediated by NGF
have been studied primarily in vitro in cell culture studies
or in vivo using animal models. However, signaling path-
ways may differ in human cells. With advances in human
induced pluripotent stem cells, it may be possible in the
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future to study NGF-induced nociceptive signaling path-
ways in sensory neuron-like cells derived from human
pluripotent stem cells, allowing for a better understanding
of the cellular role of NGF in human nociception.171
Conclusions
NGF has a well-known and multifunctional role in noci-
ceptive processing; however, the precise signaling path-
ways downstream of NGF receptor activation that mediate
nociception are complex and not completely understood.
Additionally, much of the existing knowledge derives from
studies performed in animal models, and this may not
accurately represent the human condition. However, avail-
able data establish a role for NGF in the modulation of
nociception through effects on the release of inflammatory
mediators, nociceptive ion channel/receptor activity, noci-
ceptive gene expression, and local neuronal sprouting. The
role of NGF in nociception and the generation and/or
maintenance of chronic pain have led it to become
a novel and attractive target of pain therapeutics for the
treatment of chronic pain conditions.
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